Table 2.
Individual Case Description of All 23 Patients With Neurological Complications
| Patient No./Sex/Age, y | Neurological Complication |
H/O Epilepsy | H/O Neurologic Dx |
Received Tamiflu |
LOS, d | ICU | CSF WBC, cells/µL |
CSF RBC, cells/µL |
|---|---|---|---|---|---|---|---|---|
| 1a/F/4.9 | 5 | N | N | Y | 50 | Y | 9b | 80 |
| 2a/M/15.6 | 5 | N | N | Y | 7 | N | 2b | 114 |
| 3a/M/4.5 | 5, 2a | N | Infxn | Y | 28 | Y | 0 | 3 |
| 4/F/2.1 | 1b | N | N | Y | 1 | N | 1 | 4 |
| 5/F/3.2 | 2a | Y | DD | Y | 30 | Y | ||
| 6/M/0.9 | 2b | N | Onc | Y | 5 | Y | ||
| 7/M/4.3 | 2b | Y | SZ | Y | 3 | Y | ||
| 8/M/5.3 | 2b | Y | DD | Y | 2 | Y | ||
| 9/F/6.1 | 2b | N | PCH | Y | 1 | N | ||
| 10/M/6.4 | 2b | Y | DD | Y | 4 | Y | 3 | 18 |
| 11/F/7.6 | 2b | Y | SCN1a,c | Y | 2 | Y | ||
| 12/F/9.7 | 2b | Y | SZ | Y | 6 | N | ||
| 13/F/10.2 | 2b | N | SOD | Y | 2 | N | ||
| 14/M/11.7 | 2b | Y | DD | Y | 2 | N | ||
| 15/M/13.2 | 2b | Y | DD | Y | 3 | Y | ||
| 16/M/14.5 | 2b | Y | ACCc | Y | 4 | Y | ||
| 17/F/15.5 | 2b | N | Stroke | N | 4 | Y | ||
| 18/M/12.0 | 4 | N | N | Y | 2 | Y | 1 | 1 |
| 19/F/0.7 | 4, 2a | Y | ACC | Y | 9 | N | 4 | 2 |
| 20/F/3.5 | 4, 2a | Y | DD/CP | N | 6 | Y | ||
| 21/M/19.0 | 4, 2a | Y | SCN1a, c | Y | 1 | N | ||
| 22/M/5.9 | 6b | N | N | Y | 27 | Y | ||
| 23/M/11.3 | 7c | N | N | Y | 43 | Y |
| Patient No./Sex/ Agey |
CSF Glucose Level, mg/dL |
CSF Protein Level, g/dL |
EEG | CTH | MRI | Disability at Discharge |
Disability (mo After Discharge) |
|---|---|---|---|---|---|---|---|
| 1a/F/4.9 | 54 | 0.069 | Diffuse slowing | Hypodensities in brainstem | Abnl | Mod | Mild (2.8) |
| 2a/M/15.6 | 56 | 0.040 | NL | NL | Abnl | None | |
| 3a/M/4.5 | 134 | 0.290 | Diffuse slowing | Cerebral edema | Abnl | Fatal | |
| 4/F/2.1 | 79 | 0.012 | ND | ND | ND | None | |
| 5/F/3.2 | Diffuse slowing, multifocal ED | ND | ND | Mild | Mild (1.6) | ||
| 6/M/0.9 | Diffuse slowing, multifocal ED | ND | Baseline | None | |||
| 7/M/4.3 | ND | ND | ND | None | |||
| 8/M/5.3 | ND | ND | ND | None | |||
| 9/F/6.1 | Multifocal ED | ND | ND | None | |||
| 10/M/6.4 | 76 | 0.020 | Diffuse slowing, multifocal ED | ND | ND | Mild | None (2.4) |
| 11/F/7.6 | ND | NL | ND | None | |||
| 12/F/9.7 | ND | ND | ND | None | |||
| 13/F/10.2 | ND | NL | ND | None | |||
| 14/M/11.7 | ND | ND | ND | None | |||
| 15/M/13.2 | ND | Baseline | ND | None | |||
| 16/M/14.5 | ND | ND | ND | None | |||
| 17/F/15.5 | ND | Baseline | ND | None | |||
| 18/M/12.0 | 69 | 0.019 | ND | NL | ND | None | |
| 19/F/0.7 | 73 | 0.076 | ND | ND | ND | Fatal | |
| 20/F/3.5 | Diffuse slowing | NL | ND | None | |||
| 21/M/19.0 | ND | ND | ND | Fatal | |||
| 22/M/5.9 | ND | Multifocal cortical hypodensities | Abnl | Mild | None (3) | ||
| 23/M/11.3 | Diffuse slowing, electrographic seizure |
Focal gray white junction, hypodensity | Abnl | Mild | Mild (9.5) |
Abbreviations: Abnl, abnormal; ACC, agenesis of corpus callosum; CP, cerebral palsy; CSF, cerebrospinal fluid; CTH, computed tomography of the head; DD, developmental delay; Dx, diagnosis; ED, epileptiform discharge; H/O, history of; ICU, intensive care unit; Infxn, previous encephalitis; LOS, length of stay; N, No; ND, not done; NL, normal; Onc, oncology [brain tumor]; PCH, pontocerebellar hypoplasia; RBC, CSF red blood cell count; SCN1a, Dravets; SOD, septic optic dysplasia; SZ, epilepsy only; WBC, white blood cell count; Y, yes.
SI conversion factors: To convert glucose to millimoles per liter, multiply by 0.0555. To convert protein to grams per liter, multiply by 10.0.
These 3 cases are detailed in the “Case Examples” subsection of the “Methods” section.
The CSF polymerase change reaction samples were negative for pandemic influenza A H1N1.
Cases with intractable seizures.